RightFit
RecruitingNot applicable

ONC-LEUK-2406: The Impact of Systematic Financial Navigation in Acute Myeloid Leukemia

The Impact of Systematic Financial Navigation in Acute Myeloid Leukemia "SF-NAV"

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
18 Years to 64 Years
Sex
All sexes
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study tests whether adding organized help with money concerns to usual financial support affects health and quality of life during cancer treatment. It is for adults ages 18–64 with newly diagnosed acute myeloid leukemia (AML), a cancer of the blood and bone marrow, who plan to receive strong chemotherapy.

The purpose of this research is to see how personal financial burden (financial toxicity) related to cancer affects the overall health and quality of life by evaluating the impact of systematic financial navigation in addition to standard financial distress interventions during cancer treatment.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • Can understand the study and are willing to sign a consent form.
  • Are 18–64 years old when signing the consent form.
  • Have a new AML diagnosis confirmed by the study doctor. The diagnosis date is the date of the bone marrow biopsy.
  • Plan to receive strong chemotherapy as the first treatment for AML. If treatment has started, must join within 30 days of starting it.
  • Can read and understand English, Spanish, or both.
  • The study doctor believes you can understand and follow study steps for the whole study.

Who can't join

  • Have acute promyelocytic leukemia, a specific type of AML.
  • Are not willing to receive the first round of chemotherapy for AML.
  • Have had treatment for a blood cancer before.
  • Have had a stem cell transplant using cells from another person.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: 1. Ability to understand and willingness to sign an IRB-approved informed consent. 2. Age 18-64 years at the time of consent 3. Initial diagnosis of Acute Myeloid Leukemia (AML) per investigator Note: Date of initial diagnosis is the date of the bone marrow biopsy 4. Planned intensive induction chemotherapy Note: It is acceptable if chemotherapy has been initiated at the time of enrollment as long as it is within 30 days of therapy initiation 5. Ability to read and understand the English and/or Spanish language(s) 6. As determined by the enrolling investigator, ability of the participant to understand and comply with study procedures for the entire length of the study. Exclusion Criteria: 1. Diagnosis of Acute Promyelocytic Leukemia 2. Unwilling to receive induction chemotherapy for AML 3. Previous treatment for hematologic malignancy 4. Prior allogeneic hematopoietic stem cell transplant

Study sites (2)

NC